2013
Modern Chemotherapy Mitigates Adverse Prognostic Effect of Regional Nodal Metastases in Stage IV Colorectal Cancer
Thomay AA, Nagorney DM, Cohen SJ, Sigurdson ER, Truty MJ, Burtness B, Hall MJ, Chun YS. Modern Chemotherapy Mitigates Adverse Prognostic Effect of Regional Nodal Metastases in Stage IV Colorectal Cancer. Journal Of Gastrointestinal Surgery 2013, 18: 69-74. PMID: 24002765, DOI: 10.1007/s11605-013-2329-8.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCamptothecinColorectal NeoplasmsFemaleHepatectomyHumansIrinotecanKaplan-Meier EstimateLiver NeoplasmsLung NeoplasmsLymph NodesLymphatic MetastasisMaleMiddle AgedNeoplasm StagingOrganoplatinum CompoundsOvarian NeoplasmsOxaliplatinPeritoneal NeoplasmsPrognosisRetrospective StudiesYoung AdultConceptsStage IV colorectal cancerLymph node ratioPositive regional nodesRegional lymph nodesRegional nodal metastasesColorectal cancerPositive nodesOverall survivalRegional nodesLiver metastasesLymph nodesNodal metastasisPrognostic significanceModern chemotherapyMetastatic regional lymph nodesStage IV diseasePrimary tumor resectionTertiary referral centerDate of diagnosisAdverse prognostic effectMedian OSPerioperative oxaliplatinReferral centerPrognostic factorsRetrospective review
2011
Phase II and Coagulation Cascade Biomarker Study of Bevacizumab With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma
Astsaturov IA, Meropol NJ, Alpaugh RK, Burtness BA, Cheng JD, McLaughlin S, Rogatko A, Xu Z, Watson JC, Weiner LM, Cohen SJ. Phase II and Coagulation Cascade Biomarker Study of Bevacizumab With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma. American Journal Of Clinical Oncology 2011, 34: 70-75. PMID: 20458210, PMCID: PMC3030655, DOI: 10.1097/coc.0b013e3181d2734a.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabBiomarkersBlood Coagulation FactorsDeoxycytidineFemaleGemcitabineHumansLiver NeoplasmsLymphatic MetastasisMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPancreatic NeoplasmsPeritoneal NeoplasmsSurvival RateTreatment OutcomeConceptsMetastatic pancreatic cancerPancreatic cancerArm BArm AAnti-vascular endothelial growth factor antibody bevacizumabCommon grade 3/4 nonhematologic toxicitiesGemcitabine-refractory metastatic pancreatic cancerElevated D-dimer levelsGrade 3/4 nonhematologic toxicitiesMedian progression-free survivalThrombin-antithrombin complex levelsVascular endothelial growth factor (VEGF) pathwayEndothelial growth factor pathwayConfirmed objective responsesGemcitabine-containing regimenAntitumor activityModest antitumor activitySecond-line treatmentD-dimer levelsMetastatic pancreatic adenocarcinomaProgression-free survivalThrombin-antithrombin complexGrowth factor pathwaysNonhematologic toxicityObjective response